Physician profile
Antonio Urbina
NPI 1699805200
$373,176.13
in general payments reported to CMS, 2019-2025
12 companies · $125K in 2025
The $125K reported for 2025 was more than what 99% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $18K · 2021: $34K · 2022: $45K · 2023: $52K · 2024: $58K · 2025: $125K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $105K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $72K · Travel and Lodging: $46K · Food and Beverage: $7,804 · Honoraria: $3,960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $104,508.21 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $72,197.50 |
| Travel and Lodging | $46,222.20 |
| Food and Beverage | $7,804.11 |
| Honoraria | $3,960.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $112,817.28 | 2019-2025 | Pifeltro, Steglatro, Isentress |
| Viiv Healthcare Company | $101,510.23 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $72,301.00 | 2019-2025 | Yeztugo, Descovy, Sunlenca |
| Janssen Scientific Affairs, LLC | $39,185.71 | 2019-2023 | Symtuza |
| Janssen Products, Lp | $29,059.77 | 2019-2023 | Symtuza |
| Glaxosmithkline, LLC. | $9,678.98 | 2023-2025 | |
| Theratechnologies INC. | $7,575.57 | 2021-2025 | Egrifta, Trogarzo |
| Emd Serono, INC. | $515.62 | 2021-2025 | Serostim |
| Janssen Biotech, INC. | $243.25 | 2019-2023 | Symtuza |
| Kowa Pharmaceuticals America, INC. | $233.52 | 2019 | |
| Abbvie INC. | $43.49 | 2022-2024 | |
| Lilly USA, LLC | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Urbina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.